Background Experimental studies support the anti-neoplastic effect of apo(a), but several clinical studies have reported contradictory results. The purpose of this study was to determine whether a low lipoprotein(a) [Lp(a)] concentration is related to mortality from major causes of death, especially cancer. Methods The subjects were 10,413 participants (4,005 men and 6,408 women) from a multi-center population-based cohort study in Japan (The Jichi Medical School cohort study). The average age at registration was 55.0 years, and the median observation period was 4,559 days. As the estimated hazard ratio was high for both the low and very high Lp(a) levels, we defined two Lp(a) groups: a low Lp(a) group [Lp(a)<80 mg/L] and an intermediate-to-high Lp(a) group [Lp(a)≥80]. Participants who died from malignant neoplasms (n = 316), cardiovascular disease (202), or other causes (312) during the observation period were examined. Results Cumulative incidence plots showed higher cumulative death rates for the low Lp(a) group than for the intermediate-to-high Lp(a) group for all-cause, cancer, and miscellaneous-cause deaths (p<0.001, p = 0.03, and p = 0.03, respectively). Cox proportional hazards analyses with the sex and age of the participants, body mass index, and smoking and drinking histories as covariates showed that a low Lp(a) level was a significant risk for all-cause, cancer, and miscellaneous-cause deaths (p<0.001, p = 0.003, and p = 0.01, respectively). The hazard ratio (95% CI) [1.48, 1.15–1.92] of a low Lp(a) level for cancer deaths was almost the same as that for a male sex (1.46, 1.00–2.13). Conclusions This is the first report to describe the association between a low Lp(a) level and all-cause or cancer death, supporting the anti-neoplastic effect of Lp(a). Further epidemiological studies are needed to confirm the present results.
References
[1]
Danesh J, Collins R, Peto R (2000) Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 102: 1082–1085.
[2]
Smolders B, Lemmens R, Thijs V (2007) Lipoprotein (a) and stroke: a meta-analysis of observational studies. Stroke 38: 1959–1966.
[3]
Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, et al. (2010) Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 31: 2844–2853.
[4]
Sawabe M, Tanaka N, Nakahara K, Hamamatsu A, Chida K, et al. (2009) High lipoprotein(a) level promotes both coronary atherosclerosis and myocardial infarction: a path analysis using a large number of autopsy cases. Heart 95: 1997–2002.
[5]
Jaeger BR, Richter Y, Nagel D, Heigl F, Vogt A, et al. (2009) Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 6: 229–239.
[6]
Merki E, Graham M, Taleb A, Leibundgut G, Yang X, et al. (2011) Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice. J Am Coll Cardiol 57: 1611–1621.
[7]
Parhofer KG (2011) Lipoprotein(a): medical treatment options for an elusive molecule. Curr Pharm Des 17: 871–876.
[8]
Wahl ML, Kenan DJ, Gonzalez-Gronow M, Pizzo SV (2005) Angiostatin's molecular mechanism: aspects of specificity and regulation elucidated. J Cell Biochem 96: 242–261.
[9]
Kurup A, Lin CW, Murry DJ, Dobrolecki L, Estes D, et al. (2006) Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: a phase II study from Indiana University. Ann Oncol 17: 97–103.
[10]
Lippi G, Franchini M, Salvagno GL, Guidi GC (2007) Lipoprotein[a] and cancer: anti-neoplastic effect besides its cardiovascular potency. Cancer Treat Rev 33: 427–436.
[11]
Kim JS, Chang JH, Yu HK, Ahn JH, Yum JS, et al. (2003) Inhibition of angiogenesis and angiogenesis-dependent tumor growth by the cryptic kringle fragments of human apolipoprotein(a). J Biol Chem 278: 29000–29008.
[12]
Lee K, Yun ST, Kim YG, Yoon Y, Jo EC (2006) Adeno-associated virus-mediated expression of apolipoprotein (a) kringles suppresses hepatocellular carcinoma growth in mice. Hepatology 43: 1063–1073.
[13]
Yu HK, Ahn JH, Lee HJ, Lee SK, Hong SW, et al. (2005) Expression of human apolipoprotein(a) kringles in colon cancer cells suppresses angiogenesis-dependent tumor growth and peritoneal dissemination. J Gene Med 7: 39–49.
[14]
Yu HK, Kim JS, Lee HJ, Ahn JH, Lee SK, et al. (2004) Suppression of colorectal cancer liver metastasis and extension of survival by expression of apolipoprotein(a) kringles. Cancer Res 64: 7092–7098.
[15]
Trieu VN, Uckun FM (1999) Apolipoprotein(a), a link between atherosclerosis and tumor angiogenesis. Biochem Biophys Res Commun 257: 714–718.
[16]
Yi ZF, Cho SG, Zhao H, Wu YY, Luo J, et al. (2009) A novel peptide from human apolipoprotein(a) inhibits angiogenesis and tumor growth by targeting c-Src phosphorylation in VEGF-induced human umbilical endothelial cells. Int J Cancer 124: 843–852.
[17]
Wright LC, Sullivan DR, Muller M, Dyne M, Tattersall MH, et al. (1989) Elevated apolipoprotein(a) levels in cancer patients. Int J Cancer 43: 241–244.
[18]
Van Wersch JW (1994) The behaviour of lipoprotein(a) in patients with various diseases. Scand J Clin Lab Invest 54: 559–562.
[19]
Yang HH, Chen XF, Hu W, Lv DQ, Ding WJ, et al. (2009) Lipoprotein(a) level and its association with tumor stage in male patients with primary lung cancer. Clin Chem Lab Med 47: 452–457.
[20]
K？ko？lu E, Karaarslan I, Karaarslan HM, Balo？lu H (1994) Elevated serum Lp(a) levels in the early and advanced stages of breast cancer. Cancer Biochem Biophys 14: 133–136.
[21]
Motta M, Giugno I, Ruello P, Pistone G, Di Fazio I, et al. (2001) Lipoprotein (a) behaviour in patients with hepatocellular carcinoma. Minerva Med 92: 301–305.
[22]
Samonakis DN, Koutroubakis IE, Sfiridaki A, Malliaraki N, Antoniou P, et al. (2004) Hypercoagulable states in patients with hepatocellular carcinoma. Dig Dis Sci 49: 854–858.
[23]
Denti L, Pasolini G, Cortellini P, Ferretti S, Sanfelici L, et al. (1996) Effects of androgen suppression by gonadotropin-releasing hormone agonist and flutamide on lipid metabolism in men with prostate cancer: focus on lipoprotein(a). Clin Chem 42: 1176–1181.
[24]
Kuesel AC, Kroft T, Préfontaine M, Smith IC (1992) Lipoprotein(a) and CA125 levels in the plasma of patients with benign and malignant ovarian disease. Int J Cancer 52: 341–346.
[25]
Halton JM, Nazir DJ, McQueen MJ, Barr RD (1998) Blood lipid profiles in children with acute lymphoblastic leukemia. Cancer 83: 379–384.
[26]
Ishikawa S, Gotoh T, Nago N, Kayaba K (2002) The Jichi Medical School (JMS) Cohort Study: design, baseline data and standardized mortality ratios. J Epidemiol 12: 408–417.
[27]
Nago N, Kayaba K, Hiraoka J, Matsuo H, Goto T, et al. (1995) Lipoprotein(a) levels in the Japanese population: influence of age and sex, and relation to atherosclerotic risk factors. The Jichi Medical School Cohort Study. Am J Epidemiol 141: 815–821.
[28]
Ishikawa S, Deguchi T, Hara K, Takuma S, Kayaba K, et al. (1999) Lipoprotein(a) levels and apolipoprotein(a) isoforms related to life style risk factors. J Epidemiol 9: 32–39.
[29]
Durrleman S, Simon R (1989) Flexible regression models with cubic splines. Stat Med 8: 551–561.
[30]
Gray RJ (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Statist 16: 1141–1154.
[31]
Fine JP, Gray RJ (1999) A proportional hazards model for subdistribution of a competing risk. J Am Stat Assoc 94: 196–509.
[32]
Ariyo AA, Thach C, Tracy R (2003) Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med 349: 2108–2115.
[33]
Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, et al. (2009) Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. Jama 302: 412–423.
[34]
Chien KL, Hsu HC, Su TC, Sung FC, Chen MF, et al. (2008) Lipoprotein(a) and cardiovascular disease in ethnic Chinese: the Chin-Shan Community Cardiovascular Cohort Study. Clin Chem 54: 285–291.
[35]
Arai Y, Hirose N, Nakazawa S, Yamamura K, Shimizu K, et al. (2001) Lipoprotein metabolism in Japanese centenarians: effects of apolipoprotein E polymorphism and nutritional status. J Am Geriatr Soc 49: 1434–1441.
[36]
Pepe G, Di Perna V, Resta F, Lovecchio M, Chimienti G, et al. (1998) In search of a biological pattern for human longevity: impact of apo A-IV genetic polymorphisms on lipoproteins and the hyper-Lp(a) in centenarians. Atherosclerosis 137: 407–417.
[37]
Thillet J, Doucet C, Chapman J, Herbeth B, Cohen D, et al. (1998) Elevated lipoprotein(a) levels and small apo(a) isoforms are compatible with longevity: evidence from a large population of French centenarians. Atherosclerosis 136: 389–394.
[38]
Hirose N, Arai Y, Gondoh Y, Nakazawa S, Takayama M, et al. (2004) Tokyo Centenarian Study: Aging inflammation hypothesis. Geriatrics & Gerontology International 4: S182–S185.
[39]
Noma A, Abe A, Maeda S, Seishima M, Makino K, et al. (1994) Lp(a): an acute-phase reactant? Chem Phys Lipids 67-68: 411–417.
[40]
Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, et al. (1990) Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 12: 671–675.
[41]
Ikai I, Arii S, Ichida T, Okita K, Omata M, et al. (2005) Report of the 16th follow-up survey of primary liver cancer. Hepatol Res 32: 163–172.
[42]
Yano Y, Shimokawa K, Okada Y, Noma A (1997) Immunolocalization of lipoprotein(a) in wounded tissues. J Histochem Cytochem 45: 559–568.
[43]
Lippi G, Guidi G (2000) Lipoprotein(a): from ancestral benefit to modern pathogen? Qjm 93: 75–84.
[44]
Hoover-Plow J, Hart E, Gong Y, Shchurin A, Schneeman T (2009) A physiological function for apolipoprotein(a): a natural regulator of the inflammatory response. Exp Biol Med (Maywood) 234: 28–34.
[45]
Aras D, Geyik B, Topaloglu S, Ergun K, Ayaz S, et al. (2006) Serum level of lipoprotein (a) is inversely associated with the development of coronary collateral circulation. Coron Artery Dis 17: 159–163.
[46]
Ohira T, Schreiner PJ, Morrisett JD, Chambless LE, Rosamond WD, et al. (2006) Lipoprotein(a) and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke 37: 1407–1412.
[47]
Gaw A, Boerwinkle E, Cohen JC, Hobbs HH (1994) Comparative analysis of the apo(a) gene, apo(a) glycoprotein, and plasma concentrations of Lp(a) in three ethnic groups. Evidence for no common "null" allele at the apo(a) locus. J Clin Invest 93: 2526–2534.
[48]
Jenner JL, Ordovas JM, Lamon-Fava S, Schaefer MM, Wilson PW, et al. (1993) Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study. Circulation 87: 1135–1141.
[49]
Bennet A, Di Angelantonio E, Erqou S, Eiriksdottir G, Sigurdsson G, et al. (2008) Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch Intern Med 168: 598–608.
